JP2023546316A5 - - Google Patents
Info
- Publication number
- JP2023546316A5 JP2023546316A5 JP2023515254A JP2023515254A JP2023546316A5 JP 2023546316 A5 JP2023546316 A5 JP 2023546316A5 JP 2023515254 A JP2023515254 A JP 2023515254A JP 2023515254 A JP2023515254 A JP 2023515254A JP 2023546316 A5 JP2023546316 A5 JP 2023546316A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- solvate
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063075560P | 2020-09-08 | 2020-09-08 | |
| US63/075,560 | 2020-09-08 | ||
| PCT/US2021/049365 WO2022055929A1 (en) | 2020-09-08 | 2021-09-08 | Polyvalent sting activating compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546316A JP2023546316A (ja) | 2023-11-02 |
| JP2023546316A5 true JP2023546316A5 (cg-RX-API-DMAC7.html) | 2024-09-11 |
Family
ID=80469374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515254A Pending JP2023546316A (ja) | 2020-09-08 | 2021-09-08 | 多価sting活性化組成物およびその使用法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12036319B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4210707A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023546316A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230066019A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116490193A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021340623A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023004271A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3191593A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL301190A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002797A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022055929A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114805309A (zh) * | 2022-06-07 | 2022-07-29 | 中国药科大学 | 苯并杂环类化合物及其制备方法、药物组合物和应用 |
| CN120000802A (zh) * | 2023-11-20 | 2025-05-16 | 北京大学 | 用于靶蛋白水解的聚合物及其制备方法和用途 |
| CN120242033B (zh) * | 2025-06-03 | 2025-08-22 | 合肥市第一人民医院 | 一种纳米组装体及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016506408A (ja) | 2012-12-19 | 2016-03-03 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化 |
| JP2016524593A (ja) | 2013-04-29 | 2016-08-18 | メモリアル スローン−ケタリング キャンサー センター | セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法 |
| CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| JP2016538344A (ja) | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | 癌処置としてのstingアゴニストの使用 |
| EP3233089A4 (en) | 2014-12-17 | 2018-11-14 | Lipogen LLC | Method of treating cancer with cgamp or cgasmp |
| CN109069440A (zh) * | 2016-03-02 | 2018-12-21 | 得克萨斯州大学系统董事会 | 用于免疫治疗的激活sting的纳米疫苗 |
| WO2018100558A2 (en) | 2016-12-01 | 2018-06-07 | Takeda Pharmaceutical Company Limited | Cyclic dinucleotide |
| CA3078309A1 (en) * | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Methods for administering sting agonists |
| PH12020550585A1 (en) * | 2017-11-10 | 2021-04-19 | Takeda Pharmaceuticals Co | Sting modulator compounds, and methods of making and using |
| WO2019161171A1 (en) * | 2018-02-16 | 2019-08-22 | Sperovie Biosciences, Inc. | Nanoparticle formulations of sting agonists |
| JP7250808B2 (ja) * | 2018-03-08 | 2023-04-03 | ブリストル-マイヤーズ スクイブ カンパニー | 抗がん剤としての環状ジヌクレオチド |
| EP3768685A1 (en) * | 2018-03-23 | 2021-01-27 | Takeda Pharmaceutical Company Limited | Sting modulator compounds with sulfamate linkages, and methods of making and using |
| US11096899B2 (en) * | 2018-09-07 | 2021-08-24 | Wisconsin Alumni Research Foundation | Bacterial membrane nanoparticles as an immunotherapy system for cancer treatment |
| KR20220024565A (ko) * | 2019-06-22 | 2022-03-03 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 생분해성 초-pH 민감성 중합체 |
-
2021
- 2021-09-08 MX MX2023002797A patent/MX2023002797A/es unknown
- 2021-09-08 KR KR1020237010998A patent/KR20230066019A/ko active Pending
- 2021-09-08 CN CN202180071894.1A patent/CN116490193A/zh active Pending
- 2021-09-08 WO PCT/US2021/049365 patent/WO2022055929A1/en not_active Ceased
- 2021-09-08 CA CA3191593A patent/CA3191593A1/en active Pending
- 2021-09-08 BR BR112023004271A patent/BR112023004271A2/pt unknown
- 2021-09-08 EP EP21867478.6A patent/EP4210707A4/en active Pending
- 2021-09-08 IL IL301190A patent/IL301190A/en unknown
- 2021-09-08 AU AU2021340623A patent/AU2021340623A1/en active Pending
- 2021-09-08 JP JP2023515254A patent/JP2023546316A/ja active Pending
- 2021-09-08 US US17/469,111 patent/US12036319B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003525246A (ja) | 白金化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤 | |
| RU2017104909A (ru) | Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства | |
| AU2012361581B2 (en) | Effect potentiator for antitumor agents | |
| EP4331614A1 (en) | Use of medicament in treatment of tumor disease | |
| WO2010031265A1 (zh) | 用于治疗增生性疾病的药物组合物 | |
| FI4225297T3 (fi) | Yhdistelmälääkehoito syövän hoidossa | |
| JP2003525255A (ja) | ファルネシルタンパク質トランスフェラーゼ阻害剤とさらなる抗癌剤との組み合わせ剤 | |
| JP2003525235A (ja) | 抗腫瘍ヌクレオシド誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤 | |
| CN112236147A (zh) | 包含双氟烷基-1,4-苯并二氮杂*酮化合物的组合物和其使用方法 | |
| JP2024516825A5 (cg-RX-API-DMAC7.html) | ||
| WO2024175042A1 (zh) | 药物偶联物治疗肿瘤疾病的用途及方法 | |
| JP2022502378A5 (cg-RX-API-DMAC7.html) | ||
| JP2013523867A5 (cg-RX-API-DMAC7.html) | ||
| CN117797151A (zh) | 喹啉衍生物联合化疗药物用于治疗非小细胞肺癌 | |
| CN104619324A (zh) | 治疗肿瘤的组合药物及其应用 | |
| CN101252933A (zh) | 用于治疗癌症的zosuquidar,柔红霉素和阿糖胞苷 | |
| JPH10510811A (ja) | 白金およびテルルまたはセレン化合物の併用により腫瘍の発育を減少させる方法および組成物 | |
| WO2009096245A9 (ja) | 医薬組成物又は組合せ剤 | |
| WO2016175252A1 (ja) | ピラジンカルボキサミド化合物を有効成分とする医薬組成物 | |
| EP2117539B1 (en) | A method of administering an antitumor compound | |
| KR20250044686A (ko) | G12d 돌연변이체 kras 억제 활성을 갖는 이관능성 화합물을 포함하는 항암제의 조합물 | |
| JP7311177B2 (ja) | A-NOR-5αアンドロスタン薬物と抗がん薬物との併用 | |
| AU2015355965B2 (en) | Novel PEG derivative | |
| CN117017947B (zh) | 一种肿瘤细胞膜包被富勒烯的纳米材料及其制备方法和应用 | |
| CN104619325A (zh) | 治疗肿瘤的组合药物及其应用 |